Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Enduvo, a US-based virtual and augmented reality skills training content producer aligned to University of Illinois, has obtained $4m of seed funding from investors including UL Ventures, the corporate venturing arm of safety equipment producer UL, ChicagoInno reported yesterday. The round was led by venture firm Math Venture Partners. Founded in 2017, Enduvo offers a software development platform where enterprises can devise immersivee VR or AR-based training modules for their businesses. The funding will enable it to meet demand for coronavirus content as businesses look to train employees in new workplace protocols. Enduvo emerged from Jump Arches, a partnership between University of Illinois and healthcare system OSF Healthcare.
Etisense, a France-based physiological sensing equipment spinout of Université Grenoble Alpes, has closed a €445,000 ($523,000) seed round featuring regional tech transfer office Satt Linksium. The deal was filled out by private investors including affiliates of angel syndicates Health Angels Rhône Alpes and Angels Santé. The funding will go to strengthening Etisense’s team on the way to commencing mass manufacturing of its first product, a sensor intended to track physiological changes in animals during preclinical research. Etisense was spun out of Université Grenoble Alpes’s TIMC-IMAG lab, and had previously been supported by EU and French government innovation programs, in addition to state-owned investment bank Bpifrance.
University of Maryland, Baltimore has launched US-based spinout Pumas-AI to commercialise a clinical decision-making aid for prescribing personalised drug treatments, Baltimore Business Journal reported yesterday. Pumas-AI’s software platform, dubbed Lyv, applies Bayesian-based artificial intelligence to information from electronic health records and clinical research, informing decisions on whether drugs such as anti-coagulants and next-generation cancer therapies are suitable for patients. The company extends research from the Center for Translational Medicine at the School of Pharmacy.
